Erratum to: Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments(Mol Neurobiol, Doi:10.1007/s12035-014-8953-9);Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments

Molecular Neurobiology

Volumn 52, Issue 3, 2015, Pages 1601-1617

  Hu, Juan ^a,b   Huang, He Zhou ^a   Wang, Xiang ^a   Xie, Ao Ji ^a   Wang, Xiong ^a   Liu, Dan ^a   Wang, Jian Zhi ^a   Zhu, Ling Qiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Bilateral olfactory bulbectomy; Glycogen synthase kinase 3; Hippocampus; Memory deficits

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLYCOGEN SYNTHASE KINASE 3; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PHOSPHATIDYLINOSITOL 3 KINASE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN KINASE B; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; SYNAPSIN I; SYNAPTOPHYSIN; TAU PROTEIN; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE;

ADULT; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HIPPOCAMPAL CA3 REGION; LENTIVIRINAE; LONG TERM POTENTIATION; MALE; MUSHROOM; NONHUMAN; OLFACTORY BULBECTOMY; POSTSYNAPTIC DENSITY; PRESYNAPTIC POTENTIAL; PROTEIN PHOSPHORYLATION; RAT; SMELLING DISORDER; SYNAPTIC MEMBRANE; TAUOPATHY; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ENZYMOLOGY; HIPPOCAMPUS; METABOLISM; OLFACTORY CORTEX; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LONG-TERM POTENTIATION; MALE; MALEIMIDES; MITOGEN-ACTIVATED PROTEIN KINASES; OLFACTORY CORTEX; PHOSPHATIDYLINOSITOL 3-KINASES; POST-SYNAPTIC DENSITY; RATS, SPRAGUE-DAWLEY;

EID: 84942817386     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-9066-1     Document Type: Erratum

References (86)

1. Bahar-Fuchs A, Chetelat G, Villemagne VL, Moss S, Pike K, Masters CL, Rowe C, Savage G (2010) Olfactory deficits and amyloid-beta burden in Alzheimer’s disease, mild cognitive impairment, and healthy aging: a PiB PET study. J Alzheimers Dis 22(4):1081–1087. doi:10.3233/JAD-2010-100696
2. Bahar-Fuchs A, Moss S, Rowe C, Savage G (2011) Awareness of olfactory deficits in healthy aging, amnestic mild cognitive impairment and Alzheimer’s disease. Int Psychogeriatr 23(7):1097–1106. doi:10.1017/S1041610210002371
3. Doty RL, Reyes PF, Gregor T (1987) Presence of both odor identification and detection deficits in Alzheimer’s disease. Brain Res Bull 18(5):597–600
4. Gopinath B, Anstey KJ, Sue CM, Kifley A, Mitchell P (2011) Olfactory impairment in older adults is associated with depressive symptoms and poorer quality of life scores. Am J Geriatr Psychiatry 19(9):830–834. doi:10.1097/JGP.0b013e318211c205
5. Makowska I, Kloszewska I, Grabowska A, Szatkowska I, Rymarczyk K (2011) Olfactory deficits in normal aging and Alzheimer’s disease in the polish elderly population. Arch Clin Neuropsychol 26(3):270–279. doi:10.1093/arclin/acr011
6. Gray AJ, Staples V, Murren K, Dhariwal A, Bentham P (2001) Olfactory identification is impaired in clinic-based patients with vascular dementia and senile dementia of Alzheimer type. Int J Geriatr Psychiatry 16(5):513–517
7. Royall DR, Chiodo LK, Polk MS, Jaramillo CJ (2002) Severe dysosmia is specifically associated with Alzheimer-like memory deficits in nondemented elderly retirees. Neuroepidemiology 21(2):68–73
8. Talamo BR, Rudel R, Kosik KS, Lee VM, Neff S, Adelman L, Kauer JS (1989) Pathological changes in olfactory neurons in patients with Alzheimer’s disease. Nature 337(6209):736–739. doi:10.1038/337736a0
9. Thomann PA, Dos Santos V, Toro P, Schonknecht P, Essig M, Schroder J (2009) Reduced olfactory bulb and tract volume in early Alzheimer’s disease–a MRI study. Neurobiol Aging 30(5):838–841. doi:10.1016/j.neurobiolaging.2007.08.001
10. Sanchez MM, Moghadam S, Naik P, Martin KJ, Salehi A (2011) Hippocampal network alterations in Alzheimer’s disease and Down syndrome: from structure to therapy. J Alzheimers Dis 26(Suppl 3):29–47. doi:10.3233/JAD-2011-0050
11. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J (1996) Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 103(4):455–490
12. Van Hoesen GW, Hyman BT, Damasio AR (1991) Entorhinal cortex pathology in Alzheimer’s disease. Hippocampus 1(1):1–8. doi:10.1002/hipo.450010102
13. Wesson DW, Levy E, Nixon RA, Wilson DA (2010) Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer’s disease mouse model. J Neurosci 30(2):505–514. doi:10.1523/JNEUROSCI. 4622-09.2010
14. Han F, Shioda N, Moriguchi S, Qin ZH, Fukunaga K (2008) The vanadium (IV) compound rescues septo-hippocampal cholinergic neurons from neurodegeneration in olfactory bulbectomized mice. Neuroscience 151(3):671–679. doi:10.1016/j.neuroscience.2007.11.011
15. Hozumi S, Nakagawasai O, Tan-No K, Niijima F, Yamadera F, Murata A, Arai Y, Yasuhara H, Tadano T (2003) Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav Brain Res 138(1):9–15
16. Aleksandrova IY, Kuvichkin VV, Kashparov IA, Medvinskaya NI, Nesterova IV, Lunin SM, Samokhin AN, Bobkova NV (2004) Increased level of beta-amyloid in the brain of bulbectomized mice. Biochemistry (Mosc) 69(2):176–180
17. Bobkova NV, Nesteroval IV, Dana R, Dana E, Nesterov VI, Aleksandrova Y, Medvinskaya NI, Samokhin AN (2004) Morphofunctional changes in neurons in the temporal cortex of the brain in relation to spatial memory in bulbectomized mice after treatment with mineral ascorbates. Neurosci Behav Physiol 34(7):671–676
18. Morales-Medina JC, Juarez I, Venancio-Garcia E, Cabrera SN, Menard C, Yu W, Flores G, Mechawar N, Quirion R (2013) Impaired structural hippocampal plasticity is associated with emotional and memory deficits in the olfactory bulbectomized rat. Neuroscience 236:233–243. doi:10.1016/j.neuroscience.2013.01.037
19. Chiang HC, Wang L, Xie Z, Yau A, Zhong Y (2010) PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila. Proc Natl Acad Sci U S A 107(15):7060–7065. doi:10.1073/pnas.0909314107
20. Cousin MA, Evans GJ (2011) Activation of silent and weak synapses by cAMP-dependent protein kinase in cultured cerebellar granule neurons. J Physiol 589(Pt 8):1943–1955. doi:10.1113/jphysiol.2010.200477
21. Liu MG, Wang RR, Chen XF, Zhang FK, Cui XY, Chen J (2011) Differential roles of ERK, JNK and p38 MAPK in pain-related spatial and temporal enhancement of synaptic responses in the hippocampal formation of rats: multi-electrode array recordings. Brain Res 1382:57–69. doi:10.1016/j.brainres.2011.01.076
22. Moriguchi S, Han F, Nakagawasai O, Tadano T, Fukunaga K (2006) Decreased calcium/calmodulin-dependent protein kinase II and protein kinase C activities mediate impairment of hippocampal long-term potentiation in the olfactory bulbectomized mice. J Neurochem 97(1):22–29. doi:10.1111/j.1471-4159.2006.03710.x
23. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87(6):1333–1344
24. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL (2008) The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153(Suppl 1):S428–S437. doi:10.1038/bjp.2008.2
25. Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis 9(3 Suppl):309–317
26. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP (2002) The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer’s disease. Acta Neuropathol 103(2):91–99. doi:10.1007/s004010100435
27. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3beta in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33(1):43–55. doi:10.1111/j.1365-2990.2006.00795.x
28. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58(9):1010–1019
29. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92(3):232–241
30. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, Cooke SF, Avila J, Lucas JJ, Giese KP, Stephenson J, Lovestone S (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25(1):81–86. doi:10.1111/j.1460-9568.2006.05245.x
31. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53(5):703–717. doi:10.1016/j.neuron.2007.01.029
32. Zhu LQ, Liu D, Hu J, Cheng J, Wang SH, Wang Q, Wang F, Chen JG, Wang JZ (2010) GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J Neurosci 30(10):3624–3633. doi:10.1523/JNEUROSCI. 5223-09.2010
33. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, Wang Q, Chen JG, Wang JZ (2007) Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 27(45):12211–12220. doi:10.1523/JNEUROSCI. 3321-07.2007
34. Song C, Zhang XY, Manku M (2009) Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 29(1):14–22. doi:10.1523/JNEUROSCI. 3569-08.2009
35. Wang Y, Feng W, Xue W, Tan Y, Hein DW, Li XK, Cai L (2009) Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 58(6):1391–1402. doi:10.2337/db08-1697
36. Yu JY, Taylor J, DeRuiter SL, Vojtek AB, Turner DL (2003) Simultaneous inhibition of GSK3alpha and GSK3beta using hairpin siRNA expression vectors. Mol Ther 7(2):228–236
37. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1):47–60
38. Kramar CP, Chefer VI, Wise RA, Medina JH, Barbano MF (2014) Dopamine in the dorsal hippocampus impairs the late consolidation of cocaine-associated memory. Neuropsychopharmacology 39(7):1645–1653. doi:10.1038/npp.2014.11
39. Garcia-Gutierrez MS, Ortega-Alvaro A, Busquets-Garcia A, Perez-Ortiz JM, Caltana L, Ricatti MJ, Brusco A, Maldonado R, Manzanares J (2013) Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology 73:388–396. doi:10.1016/j.neuropharm.2013.05.034
40. Hendriksen H, Meulendijks D, Douma TN, Bink DI, Breuer ME, Westphal KG, Olivier B, Oosting RS (2012) Environmental enrichment has antidepressant-like action without improving learning and memory deficits in olfactory bulbectomized rats. Neuropharmacology 62(1):270–277. doi:10.1016/j.neuropharm.2011.07.018
41. Colomina MT, Roig JL, Sanchez DJ, Domingo JL (2002) Influence of age on aluminum-induced neurobehavioral effects and morphological changes in rat brain. Neurotoxicology 23(6):775–781. doi:10.1016/S0161-813X (02)00008-6
42. Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, Sun X, Zhao L, Yu M, Xu Z, Dong W, Qin Y, Fei G, Zhong C, Xu TL (2010) Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 133(Pt 5):1342–1351. doi:10.1093/brain/awq069
43. Walling SG, Nutt DJ, Lalies MD, Harley CW (2004) Orexin-A infusion in the locus ceruleus triggers norepinephrine (NE) release and NE-induced long-term potentiation in the dentate gyrus. J Neurosci 24(34):7421–7426. doi:10.1523/JNEUROSCI. 1587-04.2004
44. Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH (2005) Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48(5):825–838. doi:10.1016/j.neuron.2005.10.033
45. Hering H, Sheng M (2001) Dendritic spines: structure, dynamics and regulation. Nat Rev Neurosci 2(12):880–888. doi:10.1038/35104061
46. Geinisman Y, Ganeshina O, Yoshida R, Berry RW, Disterhoft JF, Gallagher M (2004) Aging, spatial learning, and total synapse number in the rat CA1 stratum radiatum. Neurobiol Aging 25(3):407–416. doi:10.1016/j.neurobiolaging.2003.12.001
47. Rabenstein RL, Addy NA, Caldarone BJ, Asaka Y, Gruenbaum LM, Peters LL, Gilligan DM, Fitzsimonds RM, Picciotto MR (2005) Impaired synaptic plasticity and learning in mice lacking beta-adducin, an actin-regulating protein. J Neurosci 25(8):2138–2145. doi:10.1523/JNEUROSCI. 3530-04.2005
48. Liu XA, Zhu LQ, Zhang Q, Shi HR, Wang SH, Wang Q, Wang JZ (2008) Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. Neurochem Res 33(9):1811–1820. doi:10.1007/s11064-008-9638-4
49. Yin YY, Liu H, Cong XB, Liu Z, Wang Q, Wang JZ, Zhu LQ (2010) Acetyl-L-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats. J Alzheimers Dis 19(2):735–746. doi:10.3233/JAD-2010-1272
50. Wang S, Zhu L, Shi H, Zheng H, Tian Q, Wang Q, Liu R, Wang JZ (2007) Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5. Neurochem Res 32(8):1329–1335. doi:10.1007/s11064-007-9308-y
51. Zhou P, Chen Z, Zhao N, Liu D, Guo ZY, Tan L, Hu J, Wang Q, Wang JZ, Zhu LQ (2011) Acetyl-L-carnitine attenuates homocysteine-induced Alzheimer-like histopathological and behavioral abnormalities. Rejuvenation Res 14(6):669–679. doi:10.1089/rej.2011.1195
52. Martel G, Jaffard R, Guillou JL (2010) Identification of hippocampus-dependent and hippocampus independent memory components in step-down inhibitory avoidance tasks. Behav Brain Res 207(1):138–143. doi:10.1016/j.bbr.2009.09.047
53. Nguyen PV, Abel T, Kandel ER, Bourtchouladze R (2000) Strain-dependent differences in LTP and hippocampus-dependent memory in inbred mice. Learn Mem 7(3):170–179
54. Arnsten AF, Ramos BP, Birnbaum SG, Taylor JR (2005) Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol Med 11(3):121–128. doi:10.1016/j.molmed.2005.01.006
55. Mauna JC, Miyamae T, Pulli B, Thiels E (2011) Protein phosphatases 1 and 2A are both required for long-term depression and associated dephosphorylation of cAMP response element binding protein in hippocampal area CA1 in vivo. Hippocampus 21(10):1093–1104. doi:10.1002/hipo.20823
56. Schafe GE, Nadel NV, Sullivan GM, Harris A, LeDoux JE (1999) Memory consolidation for contextual and auditory fear conditioning is dependent on protein synthesis, PKA, and MAP kinase. Learn Mem 6(2):97–110
57. Lee I, Kesner RP (2004) Encoding versus retrieval of spatial memory: double dissociation between the dentate gyrus and the perforant path inputs into CA3 in the dorsal hippocampus. Hippocampus 14(1):66–76. doi:10.1002/hipo.10167
58. Wahl LM, Pouzat C, Stratford KJ (1996) Monte Carlo simulation of fast excitatory synaptic transmission at a hippocampal synapse. J Neurophysiol 75(2):597–608
59. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42(3 Pt 1):631–639
60. Gilbey MP, Wooster MJ (1979) Mono- and multi-synaptic origin of the early surface-negative wave recorded from guinea-pig olfactory cortex in vitro. J Physiol 293:153–172
61. Willey TJ, Maeda G, Schultz RL, Seibly WS, Horowitz JM (1983) The principal projection pathway between the olfactory bulb and the prepyriform cortex in the cat. J Neurosci Res 9(3):253–277. doi:10.1002/jnr.490090304
62. Albers MW, Tabert MH, Devanand DP (2006) Olfactory dysfunction as a predictor of neurodegenerative disease. Curr Neurol Neurosci Rep 6(5):379–386
63. Kurtz P, Schuurman T, Prinz H (1989) Loss of smell leads to dementia in mice: is Alzheimer’s disease a degenerative disorder of the olfactory system? J Protein Chem 8(3):448–451
64. Koliatsos VE, Dawson TM, Kecojevic A, Zhou Y, Wang YF, Huang KX (2004) Cortical interneurons become activated by deafferentation and instruct the apoptosis of pyramidal neurons. Proc Natl Acad Sci U S A 101(39):14264–14269. doi:10.1073/pnas.0404364101
65. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7(10):793–803
66. Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q, Deng HM, Gong CX, Grundke-Iqbal I, Iqbal K, Wang JZ (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279(48):50078–50088. doi:10.1074/jbc.M406109200
67. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27(8):1981–1991. doi:10.1523/JNEUROSCI. 4321-06.2007
68. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, Iqbal K (2010) Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285(40):30851–30860. doi:10.1074/jbc.M110.110957
69. Shahani N, Brandt R (2002) Functions and malfunctions of the tau proteins. Cell Mol Life Sci 59(10):1668–1680
70. Cowan CM, Chee F, Shepherd D, Mudher A (2010) Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy. Biochem Soc Trans 38(2):564–570. doi:10.1042/BST0380564
71. Cuchillo-Ibanez I, Seereeram A, Byers HL, Leung KY, Ward MA, Anderton BH, Hanger DP (2008) Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J 22(9):3186–3195. doi:10.1096/fj.08-109181
72. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142(3):387–397. doi:10.1016/j.cell.2010.06.036
73. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56(1):70–78
74. Harris KM, Jensen FE, Tsao B (1992) Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J Neurosci 12(7):2685–2705
75. Yuste R, Bonhoeffer T (2001) Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu Rev Neurosci 24:1071–1089. doi:10.1146/annurev.neuro.24.1.1071
76. Chaudhury S, Jain S, Wadhwa S (2010) Expression of synaptic proteins in the hippocampus and spatial learning in chicks following prenatal auditory stimulation. Dev Neurosci 32(2):114–124. doi:10.1159/000279758
77. Kennedy MB (2000) Signal-processing machines at the postsynaptic density. Science 290(5492):750–754
78. Du J, Wei Y, Liu L, Wang Y, Khairova R, Blumenthal R, Tragon T, Hunsberger JG, Machado-Vieira R, Drevets W, Wang YT, Manji HK (2010) A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A 107(25):11573–11578. doi:10.1073/pnas.0913138107
79. Kelly JP, Wrynn AS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74(3):299–316
80. Bauer M, Dopfmer S (1999) Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19(5):427–434
81. Engel T, Goni-Oliver P, Gomez de Barreda E, Lucas JJ, Hernandez F, Avila J (2008) Lithium, a potential protective drug in Alzheimer’s disease. Neurodegener Dis 5(3–4):247–249. doi:10.1159/000113715
82. Pilcher HR (2003) Drug research: the ups and downs of lithium. Nature 425(6954):118–120. doi:10.1038/425118a
83. Gould TD, Zarate CA, Manji HK (2004) Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 65(1):10–21
84. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93(16):8455–8459
85. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, Lee CM (2000) Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 97(20):11074–11079. doi:10.1073/pnas.190297597
86. Gomez-Ramos A, Dominguez J, Zafra D, Corominola H, Gomis R, Guinovart JJ, Avila J (2006) Inhibition of GSK3 dependent tau phosphorylation by metals. Curr Alzheimer Res 3(2):123–127